Cerus Corporation Form 10-Q Summary
Business context and reporting period
Cerus Corporation develops and commercializes the INTERCEPT Blood System for pathogen reduction in blood components. Platelet and plasma systems were marketed in Europe, the Commonwealth of Independent States, the Middle East and selected other regions. The red blood cell system remained in development. This unaudited Form 10-Q covers the three and nine months ended September 30, 2012, with comparisons to the corresponding 2011 periods. Prior-year results were restated for inventory costs that had previously been capitalized.
Key financial metrics
| Metric | Q3 2012 | Q3 2011 | Nine months 2012 | Nine months 2011 |
|---|---|---|---|---|
| Total revenue | $8.3 million | $9.2 million | $26.3 million | $22.6 million |
| Product revenue | $8.3 million | $7.8 million | $26.2 million | $20.7 million |
| Gross profit | $3.8 million | $4.5 million | $10.8 million | $10.3 million |
| Gross margin | 46.5% | 48.9% | 41.0% | 45.5% |
| Loss from operations | $(4.3) million | $(2.7) million | $(13.7) million | $(12.6) million |
| Net income (loss) | $(3.5) million | $2.3 million | $(14.2) million | $(9.2) million |
| Net loss per share, basic | $(0.06) | $0.05 | $(0.26) | $(0.19) |
| Net cash used in operating activities | Not separately provided | Not separately provided | $(11.0) million | $(14.6) million |
Operating margins were approximately negative 52.5% in Q3 and negative 52.2% for the nine-month period. Selling, general and administrative expense increased 16% in Q3 and 10% year to date, while research and development expense increased 5% in Q3 but declined 3% year to date. Stock-based compensation was $0.7 million in Q3 and $1.9 million year to date.
At September 30, 2012, cash and cash equivalents were $26.7 million, versus $25.5 million at December 31, 2011. Working capital was $16.2 million, down from $18.6 million. Total debt was $8.2 million, including $4.9 million current and $3.3 million non-current. The company had a $5.0 million fixed-rate growth capital loan and $3.3 million outstanding under a revolving credit line. The company was in compliance with its debt covenants.
Inventory increased to $9.7 million from $6.4 million, and accounts receivable declined to $4.0 million from $6.1 million. The company reported total liabilities of $31.7 million and an accumulated deficit of $458.1 million.
Material changes versus the prior comparable period
- Q3 product revenue increased 6% and nine-month product revenue increased 26%, primarily from higher platelet and plasma kit volumes, including higher plasma purchases by Etablissement Francais du Sang and additional customer adoption.
- Total revenue declined 11% in Q3 because government grant revenue fell from $1.5 million to zero. Nine-month total revenue increased 16%, despite government grant revenue declining 95% to $0.1 million.
- Q3 gross profit declined despite higher product revenue; the prior-year period included approximately $0.5 million of supplier minimum-purchase costs, but Q3 2012 also reflected warranty-related and inventory matters. Nine-month gross profit increased modestly, while gross margin declined due in part to product mix and manufacturing costs.
- Q3 net results shifted from income of $2.3 million to a loss of $3.5 million. The change was partly attributable to a substantially smaller non-cash gain from warrant revaluation: $0.9 million in Q3 2012 versus $5.4 million in Q3 2011.
- Cash used in operations improved by $3.5 million year to date, but financing provided $12.0 million, including $10.8 million from equity offerings and $1.0 million net from the revolving credit line. Cash generation therefore remained dependent on external financing.
- Fenwal converted all outstanding Series B preferred stock into approximately 0.3 million common shares. Cerus also sold approximately 3.5 million common shares during the first nine months under its at-the-market agreements, generating $10.6 million of net proceeds.
Guidance, outlook, risks, contingencies and unusual items
- Management expected product revenue to continue increasing as market adoption expands, but did not provide quantitative revenue or earnings guidance.
- The company did not expect government grant and cooperative-agreement revenue for the foreseeable future, if at all, after exhausting the remaining DoD grant availability.
- Management stated that available cash, product receipts and debt access were expected to fund capital requirements for at least the next twelve months, while acknowledging that additional capital will be required for the red blood cell program and potentially for plasma and other regulatory activities.
- Cerus planned a modular FDA PMA submission for the plasma system, subject to FDA review of a PMA shell. The proposed U.S. red blood cell Phase III trial required additional Phase II and in-vitro work before proceeding. European clinical and regulatory activities were also planned.
- During Q3, the company recorded $0.9 million of warranty provisions and replaced certain defective or potentially defective plasma-system disposable kits. It recorded a $1.7 million current asset for an accepted Fenwal warranty claim and wrote down $1.1 million of related unsalable inventory.
- Fenwal manufactured the platelet and plasma disposable kits and was the sole supplier under an agreement extending through December 31, 2013. Cerus also relied on sole or limited suppliers for key components, including illuminators and compound adsorption devices.
- Material risks included continuing losses, dependence on future equity or debt financing, debt covenant compliance, concentrated customers and distributors, limited product adoption, regulatory delays or failure, clinical-trial uncertainty, product liability and recalls, supply-chain interruptions, foreign-exchange volatility, intellectual-property disputes and potential inventory obsolescence.
- The company had $7.9 million of Level 3 warrant liability at September 30, 2012. Changes in the stock price and valuation assumptions could materially affect reported earnings without affecting cash.
- Contractual obligations totaled $15.6 million, including $9.1 million of debt, $2.9 million of minimum purchase commitments, $2.2 million of operating leases and $1.4 million of other commitments.
Important facts for investors to verify
- Whether product revenue growth can offset the loss of government grant funding and achieve positive operating cash flow.
- The sustainability of gross margins given plasma product mix, Fenwal manufacturing costs, supplier commitments, warranty claims and inventory write-down risk.
- Cash burn, scheduled debt repayments, revolving-line availability and compliance with minimum cash and revenue covenants.
- The timing, cost and probability of FDA acceptance and approval for the plasma PMA and red blood cell clinical programs.
- The scope and final resolution of the Q3 product nonconformity, related warranty claims and any additional customer remediation.
- Customer concentration, distributor dependence and market adoption in Europe and other commercial geographies.
- Future dilution from the remaining at-the-market equity capacity, outstanding warrants, stock options and other equity awards.